Performance Update on Biogen’s Multiple Sclerosis Drugs

In 1Q18, Biogen’s (BIIB) Tecfidera generated revenues of $987 million compared to $958 million in 1Q17. That reflected a ~3% growth on year-over-year (or YoY) basis and an ~8% decline quarter-over-quarter.

In 1Q18 in the US and international markets, Tecfidera generated revenues of $729 million and $258 million, respectively, compared to $751 million and $207 million, respectively, in 1Q17. That’s a ~3% decline and a ~25% growth, respectively, on a YoY basis.

In 1Q18, in the US and international markets, Tecfidera witnessed a 12% decline and a 6% growth, respectively, on a quarter-over-quarter basis.

The growth in patient volume in the top European markets primarily attributed to revenue growth in the international markets. In 1Q18, Tecfidera benefited $12 million due to changes in foreign exchange rates.

In the multiple sclerosis drugs market, Tecfidera’s peers in oral medications include Sanofi’s (SNY) Aubagio and Novartis’s (NVS) Gilenya.

In 1Q18, Tysabri generated revenues of $462 million compared to $545 million in 1Q17, which reflected a ~15% decline on a YoY basis. In 1Q18, Tysabri’s quarter-over-quarter revenues remained flat.

In 1Q18, in the US and international markets, Tysabri generated revenues of $250 million and $212 million, respectively, compared to $306 million and $239 million, respectively, in 1Q17. That was an ~18% and ~11% decline, respectively, on a YoY basis.

In 1Q18, in the US and international markets, Tysabri witnessed a ~1% decline and a 1% growth, respectively, on a quarter-over-quarter basis.

In 1Q18, Tysabri sales by volume in the United States remained stable compared to 4Q17. In 1Q18, Tysabri benefited $17 million due to changes in foreign exchange rates. In 1Q18 in Europe, more patients were on Tysabri therapy compared to 1Q17. Tysabri witnessed a double-digit patient growth in emerging markets in 1Q18.

In the multiple sclerosis drugs market, Tysabri’s peer in infused medications is Sanofi’s (SNY) Lemtrada.